This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McMurray, J. Articles by Pfeffer, M. Search for Related Content PubMed PubMed Citation Articles by McMurray, J. Articles by Pfeffer, M.

The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction

An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)

John McMurray, MD, FACC^_*,_*, Scott Solomon, MD, FACC, Karen Pieper, MS, Shelby Reed, PhD, Jean Rouleau, MD, FACC, Eric Velazquez, MD, Harvey White, DSc, FACC^||, Jonathan Howlett, MD^¶, Karl Swedberg, MD, PhD^#, Aldo Maggioni, MD^_**, Lars Køber, MD, PhD, Frans Van de Werf, MD, FACC, Rob Califf, MD, FACC and Marc Pfeffer, MD, PhD, FACC

^_* Department of Cardiology, Western Infirmary, Glasgow, Scotland
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
Duke University Medical Center, Durham, North Carolina
The Montreal Heart Institute, Montreal, Canada
^|| Department of Cardiology, Green Lane Hospital, Auckland, New Zealand
^¶ QE 11 Heart Function and Transplantation Clinic, Dalhousie University, Halifax, Nova Scotia, Canada
^# Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden
^_** ANMCO Research Center, Florence, Italy
Department of Cardiology University of Copenhagen, Copenhagen, Denmark
Leuven Coordinating Center, Leuven, Belgium

View larger version (19K): [in a new window]   Figure 1 Cumulative Kaplan-Meier event rates (fatal and non-fatal) in the three treatment groups in the Valsartan in Acute Myocardial Infarction Trial (VALIANT). The p values are for comparisons with captopril and are based on log-rank tests. Black line = captopril; blue line = valsartan; orange line = combination.

View larger version (19K): [in a new window]   Figure 1 Continued

View larger version (18K): [in a new window]   Figure 2 Cumulative Kaplan-Meier event-free survival rates in the combination of treatment by statin groups in Valsartan in Acute Myocardial Infarction Trial (VALIANT). The p values are for interactions of statin with valsartan versus captopril and of statin with combination therapy versus captopril (from an adjusted Cox proportional hazards model). MI = myocardial infarction.